Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly?

[1]  W. Hiddemann,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. , 1991, Blood.

[2]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[3]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Gerhartz,et al.  Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group. , 1989, Bone marrow transplantation.

[5]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Beuscart,et al.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.

[7]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[8]  B. Coiffier,et al.  Treatment of acute myeloid leukemia in elderly patients. A retrospective study , 1988, Cancer.

[9]  A. Ganser,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial. , 1989, Blood.

[10]  R. Gale,et al.  Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. , 1987, Leukemia.

[11]  R. Simon,et al.  A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. H. Cowan,et al.  Low dose cytosine arabinoside in acute myeloid leukemia: Remission is not due to differentiation induction , 1985, American journal of hematology.

[13]  F. Sigaux,et al.  Low‐dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients , 1985, Cancer.

[14]  F. Lacombe,et al.  Relationship between patients' age, bone marrow karyotype, and outcome of induction therapy in acute myelogenous leukemia , 1985, American journal of hematology.

[15]  F. Sigaux,et al.  Treatment of leukemia with low-dose ara-C: a study of 160 cases. , 1985, Seminars in oncology.

[16]  H. Tilly,et al.  Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? , 1983, Blood.

[17]  C. Bloomfield,et al.  Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia. , 1984, Cancer genetics and cytogenetics.

[18]  M. Baccarani,et al.  DIFFERENTIATION OF MYELOID LEUKAEMIC CELLS: NEW POSSIBILITIES FOR THERAPY , 1979, British journal of haematology.

[19]  L. Sachs,et al.  THE DIFFERENTIATION OF MYELOID LEUKAEMIA CELLS: NEW POSSIBILITIES FOR THERAPY , 1978, British journal of haematology.

[20]  C. Spurr,et al.  Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.